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Background: Dyslipidemia and activation of renin-angiotensin system (RAS) contribute to the progression of
chronic kidney disease (CKD). This study investigated possible synergistic effects of intrarenal RAS activation with
hyperlipidemia in renal injuries.
Methods: Apolipoprotein knockout mice were fed with normal chow diet (control) or high fat diet (HF group) for
eight weeks. Human proximal tubular epithelial cell line (HK-2) was treated without (control) or with cholesterol
(30 μg/ml) plus 25-hydroxycholesterol (1 μg/ml) (lipid group) for 24 hours. The plasma lipid profile and RAS
components were determined by clinical biochemistry assay and radiommunoassay, respectively. Collagen
deposition in kidneys was evaluated by Masson-staining. The gene and protein expressions of molecules involved
in RAS components and biomarkers of epithelial mesenchymal transition (EMT) were examined by real-time PCR,
immunochemical staining, and Western blot.
Results: The mice fed with high-fat diet showed significant hyperlipidemia with collagen deposition in renal
tubular interstitium compared to controls. The plasma levels of renin, angiotensin I, and angiotensin II were no
difference in two groups. However, the kidneys of HF group showed up-regulated RAS components, which were
positively associated with increased plasma levels of triglyceride, total cholesterol, and LDL. These effects were
further confirmed by in vitro studies. Lipid loading induced HK-2 cells underwent EMT, which was closely associated
with the increased expressions of intracellular RAS components.
Conclusions: Local RAS activation was involved in hyperlipidemia-mediated renal injuries, suggesting that there are
synergistic effects resulting from RAS activation with hyperlipidemia that accelerates the progression of CKD.
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A growing body of evidence shows that injured renal
tubular epithelial cells have been implicated in increasing
kidney matrix-producing fibroblasts and myofibroblasts
populations through the process of epithelial–mesenchy-
mal transition (EMT), ultimately leading to renal tubular
interstitial fibrosis (TIF) [1] and inevitable progressive
chronic kidney disease (CKD) [2]. Dyslipidemia is one of
the main risk factors for the progression of CKD [3]. CKD* Correspondence: mmkkll@hotmail.com
1Institute of Nephrology, Zhong Da Hospital, Southeast University School of
Medicine, Nanjing City, Jiangsu Province, P.R. China
Full list of author information is available at the end of the article
© 2013 Ni et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the oris mainly characterized by normal or low concentrations
of low-density lipoprotein (LDL) cholesterol, increased
concentrations of small dense LDL, very-low-density lipo-
protein (VLDL), intermediate-density lipoprotein (IDL),
and decreased concentrations of high-density lipoprotein
cholesterol (HDL) [4]. Persistent impaired renal function
in CKD patients is associated with a significant alteration
in lipoprotein metabolism, depending on the decline in
the glomerular filtration rate (GFR) and whether the CKD
is accompanied by inflammatory stress [5]. Reduced clear-
ance and increased plasma levels of small dense LDL par-
ticles facilitate their entrance into arterial walls, resulting
in the overproduction of inflammatory mediators andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mediated renal and vascular damage. At present, the exact
mechanisms for dyslipidemia-mediated renal injuries have
not been entirely elucidated.
In addition to dyslipidemia, the activation of the RAS
has been implicated in the progression of CKD [6].
Angiotensin II is the most powerful biologically active
product of RAS and activates at least two types of cell-
surface receptors, type 1 receptor (AT1) and type 2 re-
ceptor (AT2). Angiotensin II directly constricts vascular
smooth muscle cells, enhances myocardial contractility,
stimulates aldosterone production, stimulates sodium
and water retention, stimulates the release of catechol-
amines from the adrenal medulla and sympathetic nerve
endings, and increases sympathetic nervous system activ-
ity, which results in increased blood pressure [6]. In
addition, angiotensin II, via the AT1-dependent pathway,
causes cell proliferation, production of pro-inflammatory
mediators, and extracellular matrix synthesis, all of which
facilitates kidney damage and accelerates the progression
of CKD [7-9]. Recently, the focus of interest in the RAS
has shifted toward the role of the local RAS in kidneys
[10]. Locally produced angiotensin II induces inflamma-
tion, cell growth, cell migration, cell differentiation, and
apoptosis. Angiotensin II also regulates gene expression of
bioactive substances and activates multiple intracellular
signaling pathways, all of which may contribute to renal
injury [6]. Studies have shown that there is significant di-
versity in the mechanism of intracellular synthesis of RAS
in various cell types and pathological conditions [11]. At
present, the intracellular synthesis pathway of RAS in
renal tubular cells and its stimuli remain unclear.
Increasing evidence reveals cross-talk between dyslipidemia
and RAS activation in cardiovascular diseases [12,13].
Native or oxidized LDL, through LDL receptors and scav-
enger receptors, upregulates angiotensin-converting en-
zyme (ACE) and AT1 expression in human endothelial
cells [14,15]. On the other hand, angiotensin II facilitates
the oxidation of LDL and its uptake by smooth muscle
cells and macrophages [16,17]. Although CKD is com-
monly accompanied by dyslipidemia and RAS activation,
whether there is an interaction between these two factorsTable 1 Biochemical data on the two groups of mice (mean ±
Indexes Con
Body weight (g) 28.4
Kidney weight/body weight (mg/g) 14.0
TG (mmol/l) 3.1 ±
TC (mmol/l) 13.7
HDL (mmol/l) 1.0 ±
LDL (mmol/l) 5.8 ±
Compared to the controls, the mice fed with a high fat diet developed hyperlipidem
low-density lipoprotein. * P < 0.05 vs. control.in renal injuries is still unknown. This study was under-
taken to investigate the role of RAS activation in
hyperlipidemia-mediated renal injuries in vivo and in vitro.
Results
Hyperlipidemia was induced in HF group mice
As shown in Table 1, there were significantly increased
plasma concentrations of TG, TC, and LDL in the HF
group compared with the control group. There was no
significant difference in body weights or in the ratio of
kidney weight to body weight between the two groups.
Morphological changes of kidneys in two groups of mice
We used Masson staining to evaluate hyperlipidemia-
mediated renal pathological change in ApoE KO mice.
The results showed that there was a significant accumu-
lation of collagen fibers (stained blue) in the tubular
interstitium in the HF group, which was further con-
firmed by quantitative analysis of positive staining using
Image J software (Figure 1A and 1B).
Intrarenal, not circulatory RAS, was activated in HF group
mice
To evaluate the circulating RAS levels in the two groups
of ApoE KO mice, we measured plasma concentrations
of prorenin, renin, angiotensin I, and angiotensin II.
There was no difference in the plasma concentrations of
renin, angiotensin I, and angiotensin II between the two
groups; however, prorenin levels were significantly re-
duced in the HF group compared with the control group
(Figure 2A and 2B).
To observe the effects of hyperlipidemia on intrarenal
RAS activation and the specific location of RAS expres-
sion, we examined the protein expressions of intrarenal
RAS components in ApoE KO mice by immunohisto-
chemical staining and Western blot. There were increased
protein expressions of angiotensinogen predominantly in
the proximal tubular cells, angiotensin II in both glomeru-
lar and tubular cells, renin in juxtaglomerular apparatus
cells, ACE mainly in brush border membranes of proximal
tubules, and AT1 and AT2 in glomeruli and proximal tu-
bules in the HF group when compared to the controlSD)
trol group (n = 8) HF group (n = 8)
± 2.0 28.2 ± 1.82
± 1.8 14.2 ± 1.5
0.6 7.5 ± 2.0*
± 2.7 27.8 ± 4.0*
0.4 0.8 ± 0.34
1.5 11.6 ± 3.0*
ia. TG: triglycerides, TC: total cholesterol, HDL: high-density lipoprotein, LDL:
Figure 1 Morphological changes in the kidneys of ApoE KO mice. (A) Masson staining showed significant deposition of collagen in the
tubular interstitium of the HF group when compared with the control group (×200). (B) Quantitative analysis of fibrotic tissue stained by Masson
staining. Positive stainging was quantified by image analysis using Image J software by a point-counting technique under a 176-point grid.
The histogram represents the mean ± SD of the percentage of the field area from eight experiments. * P < 0.05 vs. control.
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Western blot analysis. The protein expressions of all RAS
components (angiotensinogen, angiotensin II, renin, ACE,
AT1 and AT2) in the kidneys of HF group were increased
compared with those of the control group (Figure 3B and
3C). These findings suggest that hyperlipidemia activates
intrarenal RAS, especially in renal tubular cells.
Correlation analysis between plasma lipid profile and
intrarenal RAS activation
We analysed the correlation between hyperlipidemia and
intrarenal RAS activation analyzed by Western blot (each
group n = 5) (Figure 4). A positive correlation was observed
between intrarenal angiotensin II expression and plasma
levels of TC (r = 0.709, P < 0.05), TG (r = 0.758, P < 0.05)
and LDL (r = 0.806, P < 0.05), while no correlation was ob-
served between angiotensin II expression and plasma HDL
level (r = −0.158, P = 0.663).
Effects of hyperlipidemia on protein expressions of
E-cadherin and α-SMA in kidneys of ApoE KO mice
We examined the protein expressions of E-cadherin and
α-SMA, which are the main biomarkers for the evalu-
ation of EMT, in kidneys of ApoE KO mice. There wasincreased α-SMA protein expression and decreased E-
cadherin protein expression in the renal tubular cells of the
HF group compared with those of the control group, as
confirmed by immunohistochemical staining (Figure 5A).
Western blot analysis reconfirmed the results from the im-
munohistochemical staining (Figure 5B and 5C). These
data strongly suggested that renal tubular cells in the HF
group underwent EMT, which might have contributed to
the progression of tubular interstitial fibrosis.Effects of lipid loading on the expressions of RAS
components in HK-2 cells
Next, we investigated whether lipid modulate RAS in
HK-2 cells by analyzing the effects of lipid loading on
the expressions of RAS components in HK-2 cells. The
media containing with 30 μg/ml cholesterol and 1 μg/ml
25-hydroxycholesterol were loaded for 24 hours in HK-2
cells. As shown in Figure 6A, there were significant in-
creased intracellular mRNA levels of angiotensinogen,
renin, ACE, AT1 and AT2 in HK-2 cells. The balance be-
tween AT1 and AT2, presented as AT1/AT2 ratio, was
also found increased under the stimulation of cholesterol
and 25-hydroxycholesterol. These results were confirmed
Figure 2 Plasma concentrations of prorenin, renin, angiotensin I, and angiotensin II in the two groups of mice (A) and (B). Plasma
concentrations of renin, angiotensin I, and angiotensin II were not significant in the two groups although the plasma prorenin level was
significantly reduced in the HF group. * P <0.05 vs. control.
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(Figure 6B).
HK-2 Cells undergo EMT under cholesterol and
25-hydroxycholesterol loading
HK-2 cells were loaded with 30 μg/ml cholesterol to-
gether with 1 μg/ml 25-hydroxycholesterol for 24 hours
to investigate the lipid effects on EMT. Normal HK-2
cells presented ovoid or cubic morphologies, forming
an epithelial monolayer with evidence of a tight cell-cell
junction (Figure 7A, I). After treatment with cholesterol
and 25-hydroxycholesterol, cells showed notable elong-
ation consistent with the morphology of myofibroblasts
(Figure 7A, II). Immunofluoresence analysis showed
that HK-2 cells in control group had typical epithelial
characteristics of high E-cadherin protein expression
and low α-SMA expression (Figure 7A, III and V). Aftertwenty-four- hours incubation with cholesterol and 25-
hydroxycholesterol, the cells had a significant reduction in
E-cadherin expression and corresponding increase in α-
SMA expression (Figure 7A, IV and VI). The mRNA and
protein expression of these markers were consistent with
the immunofluoresence results (Figure 7B, 7C, and 7D).
Discussion
Since the proposal of the “lipid nephrotoxicity hypothesis”
in 1982 [18], increasing evidence from clinical and experi-
mental studies has supported the hypothesis that lipid ab-
normalities in CKD lead to progressive renal injury,
manifested as resultant glomerulosclerosis and interstitial
fibrosis [19]. Lipid deposition, mononuclear cell infiltra-
tion and accumulation of extracellular matrix (ECM)
components are recognized as early events in the devel-
opment of glomerulosclerosis, which mimics some of the
Figure 3 Protein expressions of intrarenal RAS components in two groups of mice. (A) Immunohistochemical analysis of intrarenal RAS
expression position in the two groups of mice. AGT immunoreactivity in the proximal tubular cells, Ang II immunoreactivity in both glomerular
and tubular cells, renin immunoreactivity in juxtaglomerular apparatus cells, ACE immunoreactivity in brush border membranes of proximal
tubules as well as AT1 and AT2 immunoreactivity in the proximal tubules were increased in the HF group when compared to the control group.
(B) Western blot analysis for protein expressions of intrarenal RAS components in the two groups of mice. (C) The histogram represents mean ±
SD of the densitometric scans for the protein bands of angiotensinogen (AGT), angiotensin II (Ang II), renin, angiotensin converting enzyme
(ACE), angiotensin II type 1 receptor (AT1), angiotensin II type 2 receptor (AT2) from five experiments, normalized by β-actin. * P < 0.05 vs. control.
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Recently, studies have demonstrated that local RAS ac-
tivation, especially angiotensin II, is implicated in the
pathobiology of hypercholesterolemic atherosclerosis
[21]. Therefore, in this study, we observed the possible
roles of local RAS activation in dyslipidemia mediated
renal injury using ApoE KO mouse.
ApoE KO mouse is a classical and commercial model
widely used in the research of atherosclerosis and
hyperlipidemia-induced peripheral organs injury. ApoE
KO mouse is the first model without dietary intervention
that shows more severe and more rapid development of
atherosclerotic plaques in a model of renal damage [22].
In addition, diets containing with high fat and cholesterol
markedly accelerate plaque development in these mice[23]. Our previous studies have demonstrated that high fat
diet (Western diet) fed with ApoE KO mice for 8 weeks
can induce more severe hyperlipidemia and lipid droplet
accumulation in liver and heart [24,25].
Results showed that hyperlipidemia contributed to the
development of tubular interstitial fibrosis through EMT,
which was closely correlated with increased expressions of
local RAS components. These were confirmed by results
from in vitro study. Lipid loading induced HK-2 cells
underwent EMT through intracellular RAS activation. It
has been accepted that phenotypic alteration of kidney
cells (glomerular endothelial cells, podocytes, tubular epi-
thelial cells, etc.) leads to functional impairment and the
progression of CKD [1]. EMT, a process by which differen-
tiated epithelial cells undergo a phenotypic conversion
Figure 4 Correlation analysis between plasma lipid profile and intrarenal RAS activation. Data from the two groups were compared using
the Spearman correlation coefficient. The plasma levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein (LDL) showed a
significant positive correlation with intrarenal angiotensin II expression. P-values were two-tailed, and P < 0.05 was considered significant.
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myofibroblasts, is increasingly recognized as an integral
part of tubular interstitial fibrosis after injury [26,27].
We demonstrated that hyperlipidemia induced EMT in
the kidneys of HF group and in HK-2 cells, which could
be closely associated with ECM deposition in the tubu-
lar interstitium.
Among the potential mediators inducing EMT, the
RAS is widely acknowledged to play a central role. Our
previous studies demonstrated that RAS activation and
inflammation contributes to the development of renal
interstitial fibrosis and cardiac fibrosis via EMT [28-30].
To evaluate the RAS activation in hyperlipidemia medi-
ated renal injury in vivo, we examined the plasma levels
and tissue expressions of RAS components in the kid-
neys. The results showed that expressions of RAS com-
ponents in the kidneys were markedly upregulated in
the HF group compared with the control, suggesting that
local RAS, not circulating RAS, may play a more import-
ant role in the progression of tissue injuries. Oliveira
et al. [31] confirmed in Wistar rat models that the local
RAS could regulate left ventricular hypertrophy induced
by swimming training, independently of circulating
renin, which was in accordance with our results. A pos-
sible explanation for our circulating RAS results is that
the circulating RAS is considered an endocrine axis. An
increase in RAS components, such as the angiotensinreceptors, may decrease the concentration of other RAS
associated molecules via feedback mechanism [32]. In
addition, a possible explanation for the reduction of
plasma prorenin levels in the HF group is that prorenin
was activated without proteolysis by the binding of the
prorenin receptor [33], which contributed to the progres-
sion of glomerulosclerosis [34]. This suggests that circulat-
ing prorenin may bind to the local prorenin receptor, as a
part of local RAS, resulting in decreased levels of prorenin
in plasma. Correlation analysis between plasma levels of
the lipids with the expression of intrarenal angiotensin II
further indicated that hyperlipidemia may induce renal in-
juries partly through intrarenal RAS activation.
Since the immunohischemistry staining showed that
the morphological changes and intrarenal RAS activa-
tion in kidneys of ApoE KO mice were mainly focused
on tubular cells, we used HK-2 cells to further observe
the role of lipid on RAS activation. The results revealed
that lipid loading caused a significant up-regulation of
intracellular RAS components in mRNA and protein
levels. These data were in accordance with our in vivo
results and increasing number of studies supporting the
contention that the cholesterol metabolites are regula-
tors of the RAS activation by certain mechanism. Early
studies proved an ability of LDL cholesterol to increase
AT1 gene expression on vascular smooth muscle cells
[35] and later that oxidized LDL can also increase AT1
Figure 5 Effects of hyperlipidemia on protein expressions of α-SMA and E-cadherin (A) Immunohistochemical staining of α-SMA and
E-cadherin in kidneys. Increased expression of α-SMA and decreased expression E-cadherin were observed in the tubular interstitium of the HF
group when compared with the control group. (B) Western blot analysis for the protein expressions of α-SMA and E-cadherin in kidneys. (C) The
histogram represents mean ± SD of the densitometric scans for the protein bands of α-SMA and E-cadherin from eight experiments, normalized
by comparison with β-actin. * P < 0.05 vs. control.
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[36]. Interestingly, both AT1 and AT2 expressions in
kidneys of ApoE KO mice and in HK-2 cells were in-
creased after high lipid stimulation in this study. Trad-
itionally, Ang II, the key component of the RAS, acts
through AT1 and AT2 receptors. The AT1 regulates the
expression of profibrotic factors in kidney diseases, while
the AT2 has been thought to counteract the effects of
AT1 and to play a role in the protection of the kidney
[37]. Recently, the AT2 has also been demonstrated tobe involved in some important renal pathophysiological
processes. Wolf et al. [38] demonstrated in various cell
lines and in vivo that AT2 through activation of nuclear
factor-κB participated in renal inflammatory cell recruit-
ment, and that potential Ang II-mediated proinflammatory
effects may not be totally antagonized by the currently in-
creased clinical use of AT1 receptor antagonists, suggesting
the balance between AT1 and AT2 may be more valuable
in evaluating the kidney injury [39]. In this study, we found
that AT1/AT2 ratio was increased in vivo and in vitro,
Figure 6 Up-regulation of RAS induced by cholesterol and 25-hydroxycholesterol in HK-2 cells. HK-2 cells were made quiescent by serum-
free medium for 24 hours and then maintained in serum-free medium (control) or serum-free medium containing 30 μg/ml cholesterol together
with 1 μg/ml 25-hydroxycholesterol (lipid) for 24 hours. (A) Real-time PCR of the total RAS components mRNA prepared from HK-2 cells with
or without lipid treatment. AT1/AT2 ratio was evaluated as the balance between AT1 and AT2.β-actin was used as mRNA loading control.
(B) Western blot analysis for RAS components protein expression. (C) The histogram shows the average volume density corrected by the
housekeeping control, β-actin. Data is expressed as mean ± SD. *P < 0.05 vs. control. Angiotensinogen, AGT; angiotensin II, Ang II; angiotensin
converting enzyme, ACE; angiotensin II type 1 receptor, AT1; angiotensin II type 2 receptor, AT2.
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disrupted.
Our results and those from other studies suggest that
the effects of local RAS activity and hyperlipidemia are
not independent and that hyperlipidemia enhances local
RAS activity. Gross et al. [40] confirmed that AT1 ex-
pression was upregulated in human atherosclerotic tis-
sues. An in vitro study also showed that oxidized LDL
upregulated AT1 expression in cultured human coronary
artery endothelial cells via the activation of the nuclear
transcription factor kappa B (NF-κB) pathway [36]. Tian
et al. [41] treated db/db mice with rosuvastatin andobserved that the vasoprotective effects of rosuvastatin
are achieved by its inhibition of reactive oxygen species
production from the AT1R-NAD(P)H oxidase cascade.
Nevertheless, much about the detailed molecular mecha-
nisms is unknown and need to be elucidated.
In summary, our study in vivo and in vitro proved
novel evidence that the activation of local RAS was in-
volved in the hyperlipidemia-mediated renal tubular in-
juries by inducing EMT of renal tubular cells, thereby
accelerating ECM deposition in the tubular interstitium.
The potential synergistic effects between hyperlipidemia
and RAS activation in the progression of CKD may
Figure 7 Lipid loading induced EMT in HK-2 cells. HK-2 cells were made quiescent by serum-free medium for 24 hours and then maintained
in serum-free medium (control) or serum-free medium containing 30 μg/ml cholesterol together with 1 μg/ml 25-hydroxycholesterol (lipid) for
24 hours. (A) Morphological changes of HK-2 cells under phase contrast microscopy (I and II, Scale bar: 50 μm) and immunofluorescence analysis
of E-cadherin (III and IV, Scale bar: 25 μm) and α-SMA (V and VI, Scale bar: 25 μm) expression in cells with or without lipid treatment. (B) Real-time
PCR for E-cadherin and α-SMA mRNA expression in HK-2 cells with or without lipid treatment. β-actin was used as mRNA loading control. (C and
D) Western blot analysis for E-cadherin and α-SMA protein expression. The histogram shows the average volume density corrected by
housekeeping control, β-actin. Data are expressed as mean ± SD. *P < 0.05 vs. control. All of the data shown in these studies are representative of
at least three separate experiments.
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blood pressure, dyslipidemia, and proteinuria combined
by RAS blockade and statins are not independent com-
ponents of the treatment regimen.
Materials and methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use ofLaboratory Animals of the National Institutes of Health.
The protocol was approved by the Committee on the Ethics
of Animal Experiments of Southeast University. All surgery
was performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering.
Animals
Male apolipoprotein E knockout (ApoE KO) mice with a
C57BL/6 genetic background were provided by Animal
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maintained under a constant 12-hours photoperiod at
temperatures between 21°C and 23°C and allowed free ac-
cess to food and water. Eight-week-old ApoE KO mice fed
(randomly assigned) either a normal diet containing 4% fat
(control group, n = 8) or a high fat diet (HF group, n = 8)
containing 21% fat and 0.15% cholesterol for 8 weeks. At
the end of the experimental period, blood samples were
obtained for biochemical assays, and kidney samples were
used for histological assessments.
Plasma lipid profile analysis
At termination, the mice were euthanized and blood sam-
ples were obtained from the right ventricle for biochemical
analysis. Serum concentrations of triglyceride (TG), total
cholesterol (TC), high-density lipoprotein (HDL) and low-
density lipoprotein (LDL) were determined by automatic
analyzers (Hitachi, Japan).
Determination of angiotensin I, angiotensin II, renin and
prorenin in plasma
Plasma concentrations of angiotensinogen, angiotensin I
and angiotensin II were determined using a radioimmuno-
assay kit (Beijing North Institute of Biological Technology,
China). Plasma active renin concentrations were assessed
by measuring their ability to generate angiotensin I from
angiotensinogen. Plasma renin levels were determined by
incubating mouse plasma (10 μL diluted in water, 250 μL
final volume) with 250 μL of nephrectomized rat plasma
containing angiotensinogen levels equivalent to 5000 pg of
angiotensin I. The generated angiotensin I was then quan-
tified by radioimmunoassay. The results were expressed as
picograms of angiotensin I per milliliter of plasma per
hour of incubation. Prorenin concentrations were deter-
mined by measuring active renin levels before and after
treating plasma with bovine pancreatic trypsin (Invitrogen,
USA) at a concentration determined to yield maximum
renin activation. The prorenin level for each sample was
calculated using the total trypsin-activated renin minus
the active rennin [42].
Cell culture
Human renal proximal tubular epithelial cell line (HK-2)
cells immortalized by transduction with human papilloma
virus 16 E6/E7 genes were cultured in DMEM/F12 (1:1)
(Gibco, USA) culture medium containing 1% penicillin and
streptomycin (Invitrogen, USA), 2 mmol/L L-glutamine
(Sigma, USA), and 10% heat-inactivated fetal calf serum
(Gibco, USA). Cell cultures were maintained in an incuba-
tor with a 5% CO2 atmosphere at 37°C. At 70-80% conflu-
ence, cells were synchronized with serum-free culture
medium containing 0.2% fatty acid-free bovine serum albu-
min (BSA, Gibco, USA) for 24 hours and subsequentlystimulated with 30 μg/ml cholesterol (Sigma, USA) plus
1 μg/ml 25-hydroxycholesterol (Sigma, USA) for 24 hours.
Morphological analysis
Kidney sections were fixed with 4% buffered paraformal-
dehyde for 24 hours, washed with 70% ethanol for 24 -
hours and then embedded in paraffin. Four-micrometer
-thick sections were prepared for Masson staining and
were then examined under light microscopy. To evaluate
the extent of glomerulosclerosis and renal interstitial fi-
brosis, the renal cortex fraction occupied by fibrotic tissue
that stained positively for collagen was quantitatively eval-
uated in Masson-stained sections using Image J software
(Version 1.44). We used a point-counting technique in
consecutive microscopic fields at a final magnification of
×200 under a 176-point grid.
Immunohistochemical analysis and immunofluorescence
Localization of RAS components in mice kidney was
performed in paraffin-embedded sections. The slides
were previously deparaffinized and treated with 0.3% en-
dogenous peroxidase blocking solution for 15 minutes.
Sections were then treated sequentially with normal
nonimmune animal serum for 30 minutes and incubated
with anti-mouse polyclonal primary antibodies of
angiotensinogen (diluted 1:500, Abbiotec, USA), renin
(diluted 1:200, Santa Cruz Biotechnology Inc.,USA),
angiotensin II (diluted 1:400, Novus Biologicals, USA),
ACE (diluted 1:200, Santa Cruz Biotechnology Inc.,
USA), AT1 (diluted 1:200, Santa Cruz Biotechnology Inc.,
USA), AT2 (diluted 1:200, Santa Cruz Biotechnology Inc.,
USA), E-cadherin (diluted 1:200, Santa Cruz Biotechnology
Inc., USA) and α-smooth muscle actin (α-SMA, diluted
1:400, Abcam, UK) at 4°C overnight. Sections were then
incubated with biotin-labeled secondary antibodies (Maixin
Biotechnology Ltd., China) for 30 minutes at room tem-
perature, followed by incubation with streptomycete
antibiotin-peroxidase for another 10 minutes. Staining
was completed by 3-minute incubation with 3, 30-
diaminobenzidine substrate-chromogen, which resulted
in a brown-colored precipitate at the antigen site.
Counterstaining was performed with hematoxylin. Immu-
nohistochemical images were acquired by light microscopy.
For immunocytochemical analysis, HK-2 cells were
cultured on sterile glass coverslips in 24-well plates.
Thereafter, cultures were treated and fixed with iced
paraformaldehyde for 10 minutes, permeabilized with
0.25% Triton X-100 for 10 minutes, and blocked with
5% BSA at 37°C for an additional 30 minutes. The cells
were then incubated with primary anti-E-cadherin and
anti-α-SMA antibodies overnight at 4°C, followed by in-
cubation with Alexa Fluor labeled secondary antibody at
37°C for 1 hours. Finally, slides were examined with an
Olympus DP71 fluorescence microscope.
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Total RNA was extracted from HK-2 cells by RNAiso
plus reagent and reverse transcription was performed
using the standard reagent (Takara, Japan) in accordance
with the protocols. Real time-PCR was performed on
ABI PRISM 7300 real-time PCR System (Applied
Biosystems, USA) using SYBR Green dye. The primers
used for real-time PCR were given in Table 2. β-actin
served as internal reference gene. Results were analyzed
using Sequence Detection Software version 1.4 (Applied
Biosystems, USA). The relative gene expression of each
target was quantified against a standard curve. The pre-
PCR product of each gene was used as standard, and the
standard curve was established with a 10-fold serial dilu-
tion of the product. The standard curve was included in
all PCR runs. The equation of target gene abundance/
reference gene abundance was used to evaluate the level
of expression of each gene. All measurements were
performed in duplicate.
Western blot analysis
The total proteins from kidney homogenates of ApoE KO
mice or cell extracts were separated by sodium dodecyl sul-
fate polyacrylamide gel electrophoresis and then transferred
to a nitrocellulose membrane. After blocking with 5% skim
milk in Tris-buffered saline with 0.5% Tween 20 overnight
at 4°C, the membrane was incubated with the primary anti-
bodies of angiotensinogen, angiotensin II, renin, ACE, AT1,
AT2, E-cadherin and α-SMA for 1 hour at room
temperature, followed by incubation with the appropriate
horseradish peroxidase-conjugated secondary antibodiesfor another one hour. Finally, the signals were detected
using an ECL Advanced™ system (GE Healthcare, USA).
Relative protein levels were calculated by normalization to
the amount of β-actin protein.
Statistical analysis
All data are presented as the mean ± SD. Comparisons be-
tween different two groups were performed using an un-
paired Student’s t test before expressing the results as a
percentage of the control value. The correlation between
the plasma lipid profile and the protein expression of angio-
tensin II in kidneys of ApoE KO mice were calculated with
the Spearman rank-order correlation using SPSS 13.0 soft-
ware. A P value less than 0.05 was considered significant.
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